CAJ | 학술논문

目的探讨小细胞肺癌(SCLC)患者外周血中髓样抑制细胞(MDSCs)的表达情况及临床意义.方法采用流式细胞技术,通过抗CD11b、CD33、CD14、HLA-DR等不同荧光抗体组合鉴定SCLC患者外周血中MDSCs的细胞表面标志,分析MDSCs水平与SCLC临床病理特征的相关性.结果 36例SCLC患者外周血中存在MDSCs,其特征性细胞表面标志为CD11b+CD33+ HLA-DR-,其细胞形态属于单个核细胞.SCLC患者和健康对照者外周血单个核细胞群中CD11b+CD33+ HLA-DR-细胞(MDSCs)比例分别为(26.87±6.87)％和(11.04±3.76)％,差异有统计学意义(P ＜0.001).MDSCs的表达水平与SCLC临床分期、肿瘤转移和治疗情况有关(均P＜0.05),而与患者年龄、性别、吸烟状况及体力状态无关.肿瘤临床分期越晚,MDSCs水平越高(r=0.665,P＜0.001);伴有远处器官转移的患者,MDSCs水平越高(r=0.489,P=0.003).SCLC患者治疗后的MDSCs水平低于治疗前水平,差异具有统计学意义(P =0.003).结论 SCLC患者外周血中存在MDSCs;MDSCs水平与SCLC临床分期、肿瘤转移和治疗情况有相关性.MDSCs可能作为一种新的生物标志物辅助SCLC患者的早期筛查和预后判断.
목적 탐토소세포폐암(SCLC)환자외주혈중수양억제세포(MDSCs)적표체정황급림상의의.방법 채용류식세포기술,통과항CD11b、CD33、CD14、HLA-DR등불동형광항체조합감정SCLC환자외주혈중MDSCs적세포표면표지,분석MDSCs수평여SCLC림상병리특정적상관성.결과 36례SCLC환자외주혈중존재MDSCs,기특정성세포표면표지위CD11b+CD33+ HLA-DR-,기세포형태속우단개핵세포.SCLC환자화건강대조자외주혈단개핵세포군중CD11b+CD33+ HLA-DR-세포(MDSCs)비례분별위(26.87±6.87)％화(11.04±3.76)％,차이유통계학의의(P ＜0.001).MDSCs적표체수평여SCLC림상분기、종류전이화치료정황유관(균P＜0.05),이여환자년령、성별、흡연상황급체력상태무관.종류림상분기월만,MDSCs수평월고(r=0.665,P＜0.001);반유원처기관전이적환자,MDSCs수평월고(r=0.489,P=0.003).SCLC환자치료후적MDSCs수평저우치료전수평,차이구유통계학의의(P =0.003).결론 SCLC환자외주혈중존재MDSCs;MDSCs수평여SCLC림상분기、종류전이화치료정황유상관성.MDSCs가능작위일충신적생물표지물보조SCLC환자적조기사사화예후판단.
Objective To explore the presence,frequency and clinical value of myeloid-derived suppressor cells (MDSCs) in peripheral blood of patients with small cell lung cancer (SCLC).Methods Flow cytometry using antibodies against CD11b,CD33,CD14 or HLA-DR was conducted to explore the unique cell surface markers of MDSCs and statistical analysis was performed to explore the correlation of MDSCs and clinical features.Results MDSCs were present in 36 patients with SCLC and uniquely marked by CD11b and CD33-positive,but HLA-DR-negative on cell surfaces and possessed mononuclear phenotype.The levels of CD1 1 b + CD33 + HLA-DR-cells (MDSCs) in the SCLC patients and healthy controls were (26.87 ± 6.87) ％ and (11.04 ± 3.76) ％,respectively,with a statistically significant difference (P ＜ 0.001).MDSCs level was signfficantly associated with clinical stage and tumor distant metastasis (P ＜0.05),but not with age,sex,smoking status and performance status.The later was the clinical stage,the higher was the MDSCs level (r =0.665,P ＜ 0.001).The level of MDSCs was higher in SCLC patients with distant metastasis than in those without metastasis (r =0.489,P =0.003).The level of MDSCs was higher before treatment than after treatment and the difference was statistically significant (P =0.003).Conclusions The results of our study demonstrate the existence of MDSCs in SCLC patients and the MDSCs level is associated with SCLC stage,metastasis and treatments.MDSCs might be a novel biomarker for early diagnosis and prognosis for SCLC patients.